Characterization of Cognitive Deficits in Rats Overexpressing Human Alpha-Synuclein in the Ventral Tegmental Area and Medial Septum Using Recombinant Adeno-Associated Viral Vectors

PLoS ONE

Volumn 8, Issue 5, 2013, Pages

  Hall, Hélène ^a   Jewett, Michael ^a,b   Landeck, Natalie ^a   Nilsson, Nathalie ^a   Schagerlöf, Ulrika ^a   Leanza, Giampiero ^b   Kirik, Deniz ^a  

^a LUND UNIVERSITY   (Sweden)

^b UNIVERSITY OF TRIESTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SYNUCLEIN; APOMORPHINE; GREEN FLUORESCENT PROTEIN; PARVOVIRUS VECTOR;

AMNESIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTEROMEDIAL STRIATUM; ARTICLE; BRAIN; CELL INCLUSION; CHOLINERGIC NERVE CELL; CHOLINERGIC SYSTEM; COGNITIVE DEFECT; CONTROLLED STUDY; CORPUS STRIATUM; DIAGONAL BAND OF BROCA; DISEASE ASSOCIATION; DOPAMINERGIC NERVE CELL; FEMALE; GENE OVEREXPRESSION; HIPPOCAMPUS; HISTOPATHOLOGY; LOCOMOTION; MAZE TEST; MEDIAL SEPTUM; MESOCORTICOLIMBIC DOPAMINERGIC SYSTEM; MESOLIMBIC DOPAMINERGIC SYSTEM; NEOCORTEX; NERVE PROJECTION; NONHUMAN; NUCLEUS ACCUMBENS; PATHOGENESIS; RAT; SEPTOHIPPOCAMPAL CHOLINERGIC SYSTEM; SPATIAL LEARNING; VENTRAL TEGMENTUM; VIRUS RECOMBINANT;

ALPHA-SYNUCLEIN; ANIMALS; CHOLINE O-ACETYLTRANSFERASE; COGNITION DISORDERS; DEPENDOVIRUS; DIAGONAL BAND OF BROCA; DOPAMINE; DOPAMINERGIC NEURONS; EXTRACELLULAR SPACE; FEMALE; GENE EXPRESSION; GENETIC VECTORS; GREEN FLUORESCENT PROTEINS; HIPPOCAMPUS; HUMANS; MEMORY, SHORT-TERM; MICE, TRANSGENIC; MICRODIALYSIS; MOTOR ACTIVITY; RATS; RATS, SPRAGUE-DAWLEY; RECOMBINATION, GENETIC; SEPTUM OF BRAIN; TRANSGENES; TYROSINE 3-MONOOXYGENASE; VENTRAL TEGMENTAL AREA;

EID: 84877987961     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0064844     Document Type: Article

References (47)

1. Hirsch E, Graybiel AM, Agid YA, (1988) Melanized dopaminergic neurons are differentially susceptible to degeneration in Parkinson's disease. Nature 334: 345-348.
2. Bernheimer H, Birkmayer W, Hornykiewicz O, Jellinger K, Seitelberger F, (1973) Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations. J Neurol Sci 20: 415-455.
3. Fahn S, Libsch LR, Cutler RW, (1971) Monoamines in the human neostriatum: topographic distribution in normals and in Parkinson's disease and their role in akinesia, rigidity, chorea, and tremor. J Neurol Sci 14: 427-455.
4. Chaudhuri KR, Healy DG, Schapira AH, (2006) Non-motor symptoms of Parkinson's disease: diagnosis and management. Lancet neurology 5: 235-245.
5. Aarsland D, Larsen JP, Lim NG, Janvin C, Karlsen K, et al. (1999) Range of neuropsychiatric disturbances in patients with Parkinson's disease. J Neurol Neurosurg Psychiatry 67: 492-496.
6. Bosboom JL, Stoffers D, Wolters E, (2004) Cognitive dysfunction and dementia in Parkinson's disease. J Neural Transm 111: 1303-1315.
7. Aarsland D, Kurz MW, (2010) The epidemiology of dementia associated with Parkinson disease. J Neurol Sci 289: 18-22.
8. Braak H, Rub U, Del Tredici K, (2006) Cognitive decline correlates with neuropathological stage in Parkinson's disease. J Neurol Sci 248: 255-258.
9. McRitchie DA, Cartwright HR, Halliday GM, (1997) Specific A10 dopaminergic nuclei in the midbrain degenerate in Parkinson's disease. Exp Neurol 144: 202-213.
10. Jellinger KA, (1991) Pathology of Parkinson's disease. Changes other than the nigrostriatal pathway. Mol Chem Neuropathol 14: 153-197.
11. Nakano I, Hirano A, (1984) Parkinson's disease: neuron loss in the nucleus basalis without concomitant Alzheimer's disease. Ann Neurol 15: 415-418.
12. Dubois B, Ruberg M, Javoy-Agid F, Ploska A, Agid Y, (1983) A subcortico-cortical cholinergic system is affected in Parkinson's disease. Brain Res 288: 213-218.
13. Mattila PM, Roytta M, Lonnberg P, Marjamaki P, Helenius H, et al. (2001) Choline acetytransferase activity and striatal dopamine receptors in Parkinson's disease in relation to cognitive impairment. Acta Neuropathol 102: 160-166.
14. Perry EK, Curtis M, Dick DJ, Candy JM, Atack JR, et al. (1985) Cholinergic correlates of cognitive impairment in Parkinson's disease: comparisons with Alzheimer's disease. J Neurol Neurosurg Psychiatry 48: 413-421.
15. Wisman LA, Sahin G, Maingay M, Leanza G, Kirik D, (2008) Functional convergence of dopaminergic and cholinergic input is critical for hippocampus-dependent working memory. J Neurosci 28: 7797-7807.
16. Spillantini MG, Schmidt ML, Lee VM, Trojanowski JQ, Jakes R, et al. (1997) Alpha-synuclein in Lewy bodies. Nature 388: 839-840.
17. Braak H, Del Tredici K, Rub U, de Vos RA, Jansen Steur EN, et al. (2003) Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 24: 197-211.
18. Kirik D, Rosenblad C, Burger C, Lundberg C, Johansen TE, et al. (2002) Parkinson-like neurodegeneration induced by targeted overexpression of alpha-synuclein in the nigrostriatal system. J Neurosci 22: 2780-2791.
19. Lo Bianco C, Ridet JL, Schneider BL, Deglon N, Aebischer P, (2002) alpha-Synucleinopathy and selective dopaminergic neuron loss in a rat lentiviral-based model of Parkinson's disease. Proc Natl Acad Sci U S A 99: 10813-10818.
20. Yamada M, Iwatsubo T, Mizuno Y, Mochizuki H, (2004) Overexpression of alpha-synuclein in rat substantia nigra results in loss of dopaminergic neurons, phosphorylation of alpha-synuclein and activation of caspase-9: resemblance to pathogenetic changes in Parkinson's disease. J Neurochem 91: 451-461.
21. Eslamboli A, Romero-Ramos M, Burger C, Bjorklund T, Muzyczka N, et al. (2007) Long-term consequences of human alpha-synuclein overexpression in the primate ventral midbrain. Brain 130: 799-815.
22. Kirik D, Annett LE, Burger C, Muzyczka N, Mandel RJ, et al. (2003) Nigrostriatal alpha-synucleinopathy induced by viral vector-mediated overexpression of human alpha-synuclein: a new primate model of Parkinson's disease. Proc Natl Acad Sci U S A 100: 2884-2889.
23. Maingay M, Romero-Ramos M, Carta M, Kirik D, (2006) Ventral tegmental area dopamine neurons are resistant to human mutant alpha-synuclein overexpression. Neurobiol Dis 23: 522-532.
24. Ulusoy A, Sahin G, Bjorklund T, Aebischer P, Kirik D, (2009) Dose optimization for long-term rAAV-mediated RNA interference in the nigrostriatal projection neurons. Mol Ther 17: 1574-1584.
25. Paxinos G, Watson C (2007) The rat brain in stereotaxic coordinates. London: Academic Press.
26. Morris RGM, (1981) Spatial localization does not require the presence of local cues. Learn Motiv 12: 239-260.
27. Montoya CP, Campbell-Hope LJ, Pemberton KD, Dunnett SB, (1991) The "staircase test": a measure of independent forelimb reaching and grasping abilities in rats. J Neurosci Methods 36: 219-228.
28. Ulusoy A, Sahin G, Kirik D, (2010) Presynaptic dopaminergic compartment determines the susceptibility to L-DOPA-induced dyskinesia in rats. Proc Natl Acad Sci U S A 107: 13159-13164.
29. West MJ, (1999) Stereological methods for estimating the total number of neurons and synapses: issues of precision and bias. Trends Neurosci 22: 51-61.
30. Gage FH, Wictorin K, Fischer W, Williams LR, Varon S, et al. (1986) Retrograde cell changes in medial septum and diagonal band following fimbria-fornix transection: quantitative temporal analysis. Neuroscience 19: 241-255.
31. Gundersen HJ, Jensen EB, (1987) The efficiency of systematic sampling in stereology and its prediction. J Microsc 147: 229-263.
32. Tanji K, Mori F, Mimura J, Itoh K, Kakita A, et al. (2010) Proteinase K-resistant alpha-synuclein is deposited in presynapses in human Lewy body disease and A53T alpha-synuclein transgenic mice. Acta Neuropathol 120: 145-154.
33. Koprich JB, Johnston TH, Reyes MG, Sun X, Brotchie JM, (2010) Expression of human A53T alpha-synuclein in the rat substantia nigra using a novel AAV1/2 vector produces a rapidly evolving pathology with protein aggregation, dystrophic neurite architecture and nigrostriatal degeneration with potential to model the pathology of Parkinson's disease. Molecular Neurodegener 5: 43.
34. Decressac M, Mattsson B, Lundblad M, Weikop P, Bjorklund A, (2012) Progressive neurodegenerative and behavioural changes induced by AAV-mediated overexpression of alpha-synuclein in midbrain dopamine neurons. Neurobiol Dis 45: 939-953.
35. Masliah E, Rockenstein E, Veinbergs I, Mallory M, Hashimoto M, et al. (2000) Dopaminergic loss and inclusion body formation in alpha-synuclein mice: implications for neurodegenerative disorders. Science 287: 1265-1269.
36. Giasson BI, Duda JE, Quinn SM, Zhang B, Trojanowski JQ, et al. (2002) Neuronal alpha-synucleinopathy with severe movement disorder in mice expressing A53T human alpha-synuclein. Neuron 34: 521-533.
37. Lim Y, Kehm VM, Lee EB, Soper JH, Li C, et al. (2011) alpha-Syn suppression reverses synaptic and memory defects in a mouse model of dementia with Lewy bodies. J Neurosci 31: 10076-10087.
38. Magen I, Fleming SM, Zhu C, Garcia EC, Cardiff KM, et al. (2012) Cognitive deficits in a mouse model of pre-manifest Parkinson's disease. Eur J Neurosci 35: 870-882.
39. Masliah E, Rockenstein E, Mante M, Crews L, Spencer B, et al. (2011) Passive immunization reduces behavioral and neuropathological deficits in an alpha-synuclein transgenic model of Lewy body disease. PloS one 6: e19338.
40. Mattila PM, Rinne JO, Helenius H, Dickson DW, Roytta M, (2000) Alpha-synuclein-immunoreactive cortical Lewy bodies are associated with cognitive impairment in Parkinson's disease. Acta Neuropathol 100: 285-290.
41. Lam HA, Wu N, Cely I, Kelly RL, Hean S, et al. (2011) Elevated tonic extracellular dopamine concentration and altered dopamine modulation of synaptic activity precede dopamine loss in the striatum of mice overexpressing human alpha-synuclein. J Neurosci Res 89: 1091-1102.
42. Nuber S, Petrasch-Parwez E, Winner B, Winkler J, von Horsten S, et al. (2008) Neurodegeneration and motor dysfunction in a conditional model of Parkinson's disease. J Neurosci 28: 2471-2484.
43. Szego EM, Gerhardt E, Outeiro TF, Kermer P, (2011) Dopamine-depletion and increased alpha-synuclein load induce degeneration of cortical cholinergic fibers in mice. J Neurol Sci 310: 90-95.
44. Szego EM, Outeiro TF, Kermer P, Schulz JB, (2013) Impairment of the septal cholinergic neurons in MPTP-treated A30P alpha-synuclein mice. Neurobiol Aging 34: 589-601.
45. Larsen KE, Schmitz Y, Troyer MD, Mosharov E, Dietrich P, et al. (2006) Alpha-synuclein overexpression in PC12 and chromaffin cells impairs catecholamine release by interfering with a late step in exocytosis. J Neurosci 26: 11915-11922.
46. Nemani VM, Lu W, Berge V, Nakamura K, Onoa B, et al. (2010) Increased expression of alpha-synuclein reduces neurotransmitter release by inhibiting synaptic vesicle reclustering after endocytosis. Neuron 65: 66-79.
47. Lundblad M, Decressac M, Mattsson B, Bjorklund A, (2012) Impaired neurotransmission caused by overexpression of alpha-synuclein in nigral dopamine neurons. Proc Natl Acad Sci U S A 109: 3213-3219.